ALPS Advisors’s Ironwood Pharmaceuticals IRWD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-116,860
| Closed | -$172K | – | 1041 |
|
|
2025
Q1 | $172K | Sell |
116,860
-12,537
| -10% | -$29.9K | ﹤0.01% | 967 |
|
|
2024
Q4 | $573K | Buy |
129,397
+11,862
| +10% | +$48.1K | ﹤0.01% | 580 |
|
|
2024
Q3 | $484K | Sell |
117,535
-6,440
| -5% | -$34.6K | ﹤0.01% | 616 |
|
|
2024
Q2 | $808K | Buy |
123,975
+13,569
| +12% | +$96K | 0.01% | 510 |
|
|
2024
Q1 | $962K | Buy |
110,406
+3,104
| +3% | +$37.7K | 0.01% | 495 |
|
|
2023
Q4 | $1.23M | Sell |
107,302
-7,837
| -7% | -$77.5K | 0.01% | 419 |
|
|
2023
Q3 | $1.11M | Sell |
115,139
-9,330
| -7% | -$91.4K | 0.01% | 417 |
|
|
2023
Q2 | $1.32M | Buy |
+124,469
| New | +$1.34M | 0.01% | 402 |
|
|
2022
Q4 | – | Sell |
-83,628
| Closed | -$866K | – | 1060 |
|
|
2022
Q3 | $866K | Sell |
83,628
-15,922
| -16% | -$181K | 0.01% | 495 |
|
|
2022
Q2 | $1.15M | Buy |
+99,550
| New | +$1.17M | 0.01% | 450 |
|
|
2022
Q1 | – | Sell |
-31,115
| Closed | -$363K | – | 894 |
|
|
2021
Q4 | $363K | Buy |
31,115
+622
| +2% | +$7.63K | ﹤0.01% | 749 |
|
|
2021
Q3 | $398K | Buy |
+30,493
| New | +$394K | ﹤0.01% | 558 |
|
|
2021
Q2 | – | Sell |
-291,213
| Closed | -$3.26M | – | 911 |
|
|
2021
Q1 | $3.26M | Buy |
291,213
+2,051
| +0.7% | +$21.7K | 0.03% | 208 |
|
|
2020
Q4 | $3.29M | Buy |
289,162
+67,307
| +30% | +$737K | 0.04% | 205 |
|
|
2020
Q3 | $2M | Buy |
221,855
+4,422
| +2% | +$43.9K | 0.03% | 236 |
|
|
2020
Q2 | $2.24M | Sell |
217,433
-67,667
| -24% | -$693K | 0.03% | 226 |
|
|
2020
Q1 | $2.88M | Sell |
285,100
-30,748
| -10% | -$361K | 0.04% | 185 |
|
|
2019
Q4 | $4.2M | Buy |
+315,848
| New | +$3.48M | 0.03% | 170 |
|
|
2018
Q4 | – | Sell |
-294,079
| Closed | -$4.55M | – | 904 |
|
|
2018
Q3 | $4.55M | Buy |
294,079
+56,596
| +24% | +$895K | 0.03% | 171 |
|
|
2018
Q2 | $3.8M | Buy |
237,483
+20,665
| +10% | +$306K | 0.02% | 192 |
|
|
2018
Q1 | $2.8M | Buy |
216,818
+37,682
| +21% | +$470K | 0.02% | 187 |
|
|
2017
Q4 | $2.25M | Buy |
179,136
+20,310
| +13% | +$265K | 0.02% | 187 |
|
|
2017
Q3 | $2.1M | Buy |
158,826
+14,340
| +10% | +$197K | 0.01% | 183 |
|
|
2017
Q2 | $2.29M | Buy |
144,486
+9,757
| +7% | +$142K | 0.02% | 177 |
|
|
2017
Q1 | $1.93M | Sell |
134,729
-15,771
| -10% | -$216K | 0.01% | 179 |
|
|
2016
Q4 | $1.93M | Sell |
150,500
-47,279
| -24% | -$597K | 0.01% | 179 |
|
|
2016
Q3 | $2.63M | Sell |
197,779
-17,715
| -8% | -$207K | 0.02% | 169 |
|
|
2016
Q2 | $2.36M | Buy |
215,494
+44,350
| +26% | +$433K | 0.02% | 159 |
|
|
2016
Q1 | $1.57M | Sell |
171,144
-28,595
| -14% | -$236K | 0.02% | 164 |
|
|
2015
Q4 | $1.94M | Buy |
+199,739
| New | +$1.93M | 0.02% | 182 |
|
Other funds holding IRWD
AC
SCM
KCM
ALPS Advisors's IRWD Position: Q2 2025 in Review
ALPS Advisors sold out of Ironwood Pharmaceuticals (IRWD) in Q2 2025, closing a stake of 116,860 shares — an estimated $172K sold.
ALPS Advisors first reported a position in IRWD in Q4 2015 and held it in 30 quarters. The position peaked at $4.55M in Q3 2018. 155 funds tracked by Wall St. Rank hold IRWD as of Q2 2025.
- ALPS Advisors reported no remaining Ironwood Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
- ALPS Advisors sold 116,860 Ironwood Pharmaceuticals shares in Q2 2025, an estimated $172K.
- ALPS Advisors first reported a position in Ironwood Pharmaceuticals in Q4 2015 and held it in 30 quarters.
- ALPS Advisors's Ironwood Pharmaceuticals position peaked at $4.55M in Q3 2018.
- 155 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q2 2025.
Based on ALPS Advisors's 13F filing for Q2 2025, filed 11 Aug 2025.